About: http://data.cimple.eu/news-article/a4b3c7f220839856d4087769aa6589e61091b1d64b588eda838b546d

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/a4b3c7f220839856d4087769aa6589e61091b1d64b588eda838b546d Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	German chemicals giant Bayer reported Tuesday a second-quarter net loss of 9.55 billion euros ($11.26 billion), reflecting the "exceptional impact" of a US settlement of thousands of claims that its glyphosate weed killer may have caused cancer. The heavy loss compared with a profit of 404 million euros ($475 million) in the same quarter of the previous year. The huge loss came as Bayer signed in June an agreement worth between $8.8 billion and $9.6 billion to settle some 125,000 claims in the US over the Roundup weed killer it acquired when it bought American agrochemical group Monsanto in 2018. However, in July the company said it was reviewing plans to resolve future litigation after a California judge criticised part of the proposed settlement. Bayer said at the time that the motion for court approval of the $1.25 billion deal -- which addresses future claims in the US -- had been withdrawn to "enable the parties to more comprehensively address the questions" raised. In addition, Bayer's pharmaceuticals division took a charge of 1.25 billion euros in the second quarter for litigation, primarily for its permanent birth-control medical device Essure. The company said it was also hit by the fallout from the coronavirus pandemic, noting that restrictions to prevent transmission of the virus had led to the postponement of non-urgent treatments -- thereby dampening demand for women's health, ophthalmology and radiology products. Stockpiling in the first quarter added to a slight decline in business, although there was "a slight recovery trend toward the end of the second quarter," the group said. In the three months to June, sales fell 2.5 percent compared with the same period of last year to 10.7 billion euros. Bayer trimmed its guidance for the year and said it now expects sales for this year to slip to between 43 and 44 billion euros, down from its earlier forecast of between 44 and 45 billion. Shares in Frankfurt are down 3.3 percent, recovering slightly from an earlier fall of 3.9 percent. edf/hmn/rl
schema:headline	Bayer posts 9.5 bn euro loss on glyphosate settlement
schema:mentions	Agrochemical Medical device Ophthalmology EDF Energy Bayer Herbicide Frankfurt Glyphosate Monsanto Ebola virus disease Court Cancer California Pandemic United States Severe acute respiratory syndrome coronavirus 2 Essure Radiology
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-08-04 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	60 (xsd:integer)
http://data.cimple...tology#hasEmotion	fear

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software